Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
Tevogen Bio Inc Acquire cell therapy manufacturing facility with clinical and commercial capabilities Further ExacTcell platform for additional clinical trials based on successful completion of POC Highlight full year financial results and clarify key financial items WARREN, N.J., May 01, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a